TerrAscend Reports $81.3M Net Loss, Declining EBITDA, and $41.2M Michigan Exit Impairment in 2025 Annual Report

summarizeSummary

TerrAscend Corp. reported a net loss of $81.3 million for fiscal year 2025, alongside declining Adjusted EBITDA and a significant impairment from its Michigan market exit, while facing increasing debt and uncertain tax liabilities.

check_boxKey Events

• Reported Substantial Net Loss and Declining Profitability

  The company reported a net loss of $81.3 million for fiscal year 2025, an increase from $72.7 million in 2024. Adjusted EBITDA from continuing operations decreased to $67.8 million in 2025 from $70.2 million in 2024, indicating a decline in core operational profitability.

• Significant Impairment from Michigan Market Exit

  TerrAscend incurred a $41.2 million impairment loss in 2025 related to its planned exit from the Michigan market, which is expected to be completed in the first half of 2026. This contributed significantly to the overall net loss.

• Increased Debt and Uncertain Tax Liabilities

  Total loans payable increased to $225.4 million as of December 31, 2025, from $204.5 million in 2024. The liability for uncertain tax positions, primarily due to IRC Section 280E, rose to $128.8 million, posing a substantial financial risk.

• Potential Cannabis Rescheduling and Regulatory Risks

  The filing notes President Trump's executive order to expedite moving marijuana from Schedule I to Schedule III, which could alleviate the impact of Section 280E. However, the process is not self-executing, and future legislation could still maintain adverse tax treatment, with the company currently under IRS examination for tax years 2021-2023.

auto_awesomeAnalysis

TerrAscend Corp.'s 2025 annual report highlights a challenging financial year, marked by a significant net loss and a decrease in Adjusted EBITDA from continuing operations. The company incurred a substantial impairment loss related to its planned exit from the Michigan market, further impacting its financial results. The filing also reveals an increase in total debt and a growing liability for uncertain tax positions, primarily due to the federal illegality of cannabis and the implications of IRC Section 280E. While an executive order to expedite cannabis rescheduling offers a potential long-term positive, its immediate impact on the company's tax burden and banking access remains uncertain. Investors should closely monitor the company's ability to manage its debt, navigate the complex regulatory environment, and improve profitability amidst intense market competition.